Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude CRT misses launch target

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical now expects to launch the Epic HF and Atlas+ HF resynchronization ICDs in July, following meetings with FDA reviewers, the company announces May 14. The firm previously had predicted FDA would approve both heart failure devices in time for a formal launch at the 2004 NASPE/Heart Rhythm Society Annual Scientific Sessions in San Francisco May 19-22. "FDA has not advised St. Jude of any substantive concerns with the PMA application or identified any open issues requiring the company's response," St. Jude explains in a release. The PMAs for both the Epic HF and Atlas+ HF are based on results from the RHYTHM ICD trial, which the company released at the American College of Cardiology conference in March...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel